EP1001685B1 - Nahrungszusammensetzungen enthaltend methionin - Google Patents

Nahrungszusammensetzungen enthaltend methionin Download PDF

Info

Publication number
EP1001685B1
EP1001685B1 EP98935394A EP98935394A EP1001685B1 EP 1001685 B1 EP1001685 B1 EP 1001685B1 EP 98935394 A EP98935394 A EP 98935394A EP 98935394 A EP98935394 A EP 98935394A EP 1001685 B1 EP1001685 B1 EP 1001685B1
Authority
EP
European Patent Office
Prior art keywords
methionine
food composition
composition according
vitamin
daily dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
EP98935394A
Other languages
English (en)
French (fr)
Other versions
EP1001685A1 (de
Inventor
Robert Johan Joseph Hageman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutricia NV
Original Assignee
Nutricia NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8228562&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1001685(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nutricia NV filed Critical Nutricia NV
Priority to EP98935394A priority Critical patent/EP1001685B1/de
Priority to DK98935394T priority patent/DK1001685T3/da
Publication of EP1001685A1 publication Critical patent/EP1001685A1/de
Application granted granted Critical
Publication of EP1001685B1 publication Critical patent/EP1001685B1/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a module of nutritional components which supports total methionine metabolism in man, for use in a universal medicinal food.
  • the invention also relates to food products containing this module and to a method of producing food products by using selected amounts of the module.
  • Methionine is metabolised in man via a multi-step pathway, the transsulfuration pathway.
  • Several intermediate products are formed in this pathway, which play a dominant role in other biochemical pathways as well.
  • the reaction product S-adenosyl methionine is extensively used in many methylation reactions; homocysteine is the main methyl acceptor in folate metabolism and also the conversion of betaine to dimethylglycine (via methylation of homocysteine) strongly influences folate metabolism.
  • cystathionine generated by reaction between homocysteine and serine, that may split into cysteine and 2-oxybutyrate. The latter is involved in the metabolism of several other compounds (e.g. threonine). Cysteine is metabolised to various useful products such as taurine and sulphates. It is also an important precursor for glutathione in the liver and some other tissues. Glutathione that is produced in the liver has to be transported to cell compartments in some peripheral organs in order to exhibit its activity. Intracellular glutathione levels are in turn strongly influenced by the presence of reducing equivalents and amino acids in the cell.
  • total methionine metabolism as those biochemical pathways which occur in mammals and in which metabolites of the methionine transsulfuration pathway (methionine, S-adenosyl methionine, S-adenosyl homocysteine, homocysteine, cystathionine and cysteine) and main metabolites thereof (taurine and glutathione) are involved (see scheme below).
  • Dysfunction of methionine metabolism may also lead to increased homocysteine plasma levels, which are associated with cardiovascular problems. Cysteine deficiencies may lead to low taurine levels, low sulphation capacity and low intracellular glutathione levels. Shortages of cysteine have been associated with diseases like diabetes, cardiovascular disease, cancer, rheumatoid arthritis, etc.
  • Glutathione can play many important roles in the cell. A substantial part of glutathione must be in the reduced form (having a specific redox potential) in order to allow it to be active. Deficiencies of glutathione have been associated with all kinds of radical-mediated diseases, such as chronic inflammations, rheumatoid arthritis, with the occurrence of cancer and impaired immune functions against infection.
  • EP-A-532369 (Bissbort) describes the pharmaceutical use of L-methionine for enhancing the methylation capacity in man, e.g. for improving the immune response, combating viral infections and increasing creatine production.
  • Methionine may be combined with folic acid, pyridoxine (vitamin B 6 ), cyanocobalamine (vitamin B 12 ) and magnesium.
  • a daily dose comprises 1.5-5 g (3 g) of L-methionine, 250-2500 mg (600 mg) of magnesium chloride, 30-120 mg (100 mg) of magnesium carbonate, 0.6-20 mg (8 mg) of folic acid, 1.5-25 mg (10 mg) of vitamin B 6 and 15-25 ⁇ g (20 ⁇ g) of vitamin B 12 .
  • WO 93/15738 discloses medicaments containing thymine or its equivalents in combination with methionine, pyridoxine and/or cyanocobalamine and optionally penicillin G for the treatment of disorders in the folate metabolism.
  • WO 96/02252 and WO 96/33727 disclose the use of S-adenosyl-L-methionine for the treatment of damage caused by temporary and permanent local ischaemias, respectively.
  • EP-A-347864 discloses an anti-atherogenic agent which lowers the plasma level of free sulphydryl groups of homocysteine and cysteine and which can contain oxidising agents and folic acid, pyridoxine (vitamin B 6 ), cyanocobalamine (vitamin B 12 ) and choline or betaine.
  • EP-A-595005 and EP-A-595006 teach the use, for adults and infants respectively, of specific ratios of folic acid, pyridoxine and cyanocobalamine for suppressing high homocysteine and methionine levels in plasma, which are the cause of metabolic disturbances.
  • pyridoxine should at least partly be present in its accessible pyridoxal form.
  • Riboflavin (vitamin B 2 ), ascorbic acid (vitamin C), tocopherol (vitamin E), zinc and selenium may also be present.
  • EP-A-705542 discloses a complete dietary composition for adolescents and especially for children of 1 to 6 years having diseases such as intestinal disorders.
  • the composition contains 50-65 (63) energy % of carbohydrates, 20-35 (25) en.% of fats and 10-20 (12) en.% of free amino acids with a specific amino acid content.
  • a multivitamin preparation supporting the immune system is disclosed in GB-A-2,292,522. It contains an amino acid blend, vitamins C, E, A, D and B complex, minerals and trace elements. Important amino acids are: methionine (90 mg), valine, leucine, threonine (70 mg), phenylalanine, lysine, isoleucine and tryptophane. Levels of B complex vitamins may be: B1 (50 mg), B2 (100 mg), B6 (100 mg), pantothenic acid (300 mg), nicotinamide (50 mg), B12 (2.5 ⁇ g), folic acid (150 ⁇ g) and biotin (50 ⁇ g). The preparation does not contain carbohydrates or full proteins. No recommended dosages are given.
  • US 5,215,750 discloses a composition for inducing weight loss, containing glutamine as the major component, and further a broad range of vitamins and minerals, without further amino acids, proteins, carbohydrates or fats.
  • the reactive species are also easily oxidised in aqueous solution, and it is therefore an object of the invention to provide a nutritional composition with a sufficient shelf stability.
  • Some nutritional components that play an important part in the methionine metabolism have bad organoleptic properties. It is therefore an object of the invention to provide a nutritional product that is well acceptable to the consumer.
  • Such other components comprise end products and intermediates for giving a more rapid response and for meeting requirements for those patients that have deficiencies in one or more key enzymes that are involved in total methionine metabolism.
  • the invention pertains to an enteral food composition containing at least digestible, in particular glucose or ⁇ -glucan, carbohydrates and proteins or protein hydrolysates and a combination of active components as defined in the appending claims.
  • the amounts of the components of the food composition of the invention are related to the Recommended Daily Allowance (RDA) and other recommendations as used in standard nutrition literature.
  • RDA Recommended Daily Allowance
  • the reference values based on these RDA values for components that can be used according to the invention, together with the preferred ranges of total intake per day, are given in table 1 below.
  • the reference values are based on healthy adults having a body weight of 70 kg. For patients of different condition and different body weight, the levels should be adapted accordingly. It is to be understood that on average the energy intake per day should be about 8374 kJ ( 2000 kcal).
  • Nutritional equivalents of amino acids include di- or oligopeptides incorporating said amino acid, esters, amides and salts of the amino acids, as well as S-substituted derivatives in the case of sulphur-containing amino acids, including methionine, S-acetylmethionine, S-acetylhomocysteine, homocysteine, cystathionine, cysteine, cystine, glutathione and other dimers and trimers derived from these.
  • the sulphur amino acids other than methionine and cysteine can be used instead as a substitute of methionine and cysteine, although the latter two are preferred.
  • cysteine equivalent Suitable examples of a cysteine equivalent are N-acetylcysteine and bisglycylcystine. Proteins may also be used as amino acid sources, provided that the desired amino acids become readily available by digestion. Methionine-rich proteins include e.g. casein, caseinates and casein hydrolysates. Cysteine-rich proteins include dairy whey proteins and specific proteins thereof such as lactalbumin, as well as blood proteins, egg proteins and other proteins which are rich in sulphur-containing amino acids and hydrolysates thereof. Thus the required level of sulphur-containing amino acids can be attained e.g.
  • casein by combining casein with cysteine, N-acetylcysteine or a cysteine-rich peptide or by combining whey protein with methionine or a methionine-rich peptide.
  • proteins that are rich in essential amino acids are also present.
  • Nutritional equivalents of pyridoxal include pyridoxal phosphate, pyridoxine and pyridoxamine and salts and the like.
  • Nutritional equivalents of niacin include niacinamide (nicotinamide) and tryptophan.
  • the preferred equivalent of thiamine (vitamin B 1 ) is its hydrochloride.
  • methionine/cysteine, folic acid, pyridoxal and zinc should be present in addition to the energy content. These components, including the carbohydrate content, were found to be essential as primary support of the transsulfuration pathway. At least half of the methionine/cysteine content should consist of methionine or a methionine equivalent.
  • a second group of important components includes magnesium, cyanocobalamine and betaine/choline. Preferably, at least one of these is also present in the food compositions of the invention. Magnesium is preferred, but at around or slightly above the reference level only. Suitable magnesium salts include magnesium hydrogen phosphate and magnesium sulphate.
  • a third group comprises transsulfuration products, including creatine, carnitine, taurine and nucleotides. At least one of these is also advantageously present in the food composition.
  • a fourth group of components is important as they stimulate carbohydrate metabolism and produce ATP and reducing equivalents. At least one member of this group which includes pyruvate, thiamine, riboflavin, niacin, biotin and thioctic acid, is preferably present as well.
  • a final group comprises ascorbic acid, tocopherol, selenium, copper and manganese. The incorporation of ascorbic acid and/or tocopherols is preferred for ensuring that reduced glutathione is spared from excessive attack by radicals or oxidation processes.
  • Ascorbic acid may be present as a nutritionally acceptable salt, and tocopherol as any one or a combination of isomers, e.g. tocopherol.
  • Other antioxidants or radical scavengers like carotenoids, flavonoids, uric acid etc. may be included as well.
  • the trace elements Cu, Se and Mn are preferably included, as they are essential for key enzymes that neutralise oxygen-containing radicals.
  • the preferred range for Cu and Mn is 2-5 times the reference value; for selenium it is about 1.5 times the reference value.
  • the other components of table 1 are also preferred individually, i.e. the selection of a single component, e.g. riboflavin or manganese, forms a distinct embodiment of the invention.
  • Components for which a reference level is not given in table 1, are also advantageously incorporated in the composition of the invention.
  • the methyl donor betaine N,N,N-trimethylglycine, as its inner salt or its hydrochloride
  • one of its precursors choline and phosphatidylcholines is preferably included in order to stimulate an independent pathway for the conversion of homocysteine to methionine.
  • betaine itself is preferred over its equivalents.
  • Creatine N-guanidyl-N-methylglycine
  • L-Camitine can be given as such (inner salt) or as its hydrochloride.
  • Creatine and/or carnitine are especially preferred for patients having a poor blood circulation, or suffering from local ischaemic conditions.
  • D-Biotin (generally preferred) and taurine can be included as such, taurine especially for infants and neurological patients.
  • Nucleotides can also be advantageously included, preferably as yeast extract in an amount of about 0.1-4 g/day, for example in products for the treatment of inflammatory diseases of the gut.
  • Pyruvate is another component that can contribute to the ATP production and can protect glutathione as a radical scavenger.
  • the preferred level is from 2 to 20 g/day, especially 4-8 g/day.
  • Pyruvate can be incorporated e.g. as free acid or as its Ca, Na or K salt.
  • DL-Thioctic acid lipoic acid
  • Niacin, riboflavin and thiamine also stimulate carbohydrate metabolism and produce ATP and reducing equivalents.
  • compositions should comprise sufficient levels of essential amino acids such as lysine in accessible form, so that the total intake corresponds at least to the reference levels.
  • Some non-essential amino acids are also preferably included in the composition of the invention. These comprise especially serine, and furthermore glutamine and arginine/omithine at the indicated levels as such (L-form) or as easily degradable peptides or proteins.
  • Threonine is preferably not present in important amounts, i.e. preferably lower than 5.2 g per 6.25 g of nitrogen ( ⁇ 5.2 g per 100 g of proteinaceous material). Proteins which are low in threonine include acid whey.
  • the compositions contain carbohydrates, preferably proteins and preferably fats. In a complete food, the carbohydrates should constitute at least 25% of the required energy content, i.e. at least 1675 kJ ( 400 kcal)/day, up to 6280 kJ ( 1500 kcal)/day.
  • the carbohydrates can comprise mono-, di-, oligo- and polysaccharides, such as glucose, fructose, maltose, sucrose, fructo-, galacto- and especially gluco-oligosaccharides, starch, starch hydrolysates and starch fractions and the like.
  • the carbohydrate composition can be adapted to the type of patients.
  • the carbohydrate compositions is low in lactose.
  • the compositions may furthermore contain dietary fibres such a non-digestible carbohydrates.
  • the proteins may be those described above as sources for the desired amino acids, including milk proteins, egg proteins, blood proteins. For reasons of taste, it is preferred that at least half of the total proteinaceous material (proteins, hydrolysates and amino acids) is in the form of proteins or peptides, especially in the form of intact proteins.
  • the fats may comprise normal fats C 12 -C 18 derived from saturated and especially unsaturated fatty acids.
  • the fats may include medium chain triglycerides derived from C 8 and C 10 fatty acids (e.g. accounting for 5-40 wt.% of the fats), and preferably polyunsaturated long-chain ( ⁇ C 18 ) fats (PUFA's) derived from ⁇ -3 fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (preferably at least 3 wt.%, in particular 5-15 wt.% of the fats).
  • the ⁇ -3/ ⁇ -6 ratio is preferably from 0.3 to 3.
  • the fat content is preferably more than 30 % of the total energy content, especially more than 35 en.%, up to 45 en.%.
  • the fats should contain phospholipids such as lecithin or an equivalent thereof at a level of 1-20 wt.% of the fat content, or 0.3-10 en.%, preferably 0.6-5 en.% of the composition.
  • the phospholipids can be partly (i.e. the amount above 5 wt.% of the fat content) substituted by equivalents such as choline or betaine.
  • the food composition can have the form of a complete food, i.e. can meet all the nutritional needs of the user. As such it will usually containing 5024-10467 kJ ( 1200-2500 kcal) per daily dosage, apart from higher or lower amounts in exceptional cases.
  • the daily dosage amounts are given with respect to a daily energy supply of 8374 kJ ( 2000 kcal), but can be adapted accordingly.
  • the complete food can be liquid, wherein the daily dosage is contained in e.g. 2000 ml; more diluted or, especially, more concentrated liquids can also be used.
  • the composition can also be in solid form for reconstitution with water.
  • the complete food can be in the form of multiple dosage units, e.g. from 3 to 10 per day.
  • the food composition of the invention can also be a food supplement to be used in addition to a non-medicinal food, containing less than 6280 kJ ( 1500 kcal), in particular 1675-4187 kJ ( 400-1000 kcal), per daily dosage.
  • Such food supplement preferably also contains at least part of the carbohydrate and protein supply, so that the need of essential amino acids and serine is met with the supplement.
  • a very useful supplement contains the essential components at the levels indicated above (methionine/cysteine, folic acid, vitamin B 6 , zinc and optionally magnesium, vitamin B 12 , betaine/choline, serine and/or tryptophan with a suitable carrier such as maltodextrin in dry form, e.g. in sachets of 10 g.
  • the content of the sachet may be added to regular food or to food components so as to provide the daily doses according to the invention.
  • the invention also relates to a process of producing a food composition, which comprises preparing a premix of at least said methionine/cysteine, folic acid, pyridoxal and zinc, optionally with a relatively small amount of maltodextrin or other carbohydrate as a carrier. Further components are then added to said premix, for example by subsequent addition of other premixes.
  • premixes may simplify and/or standardise the preparation of especially adapted food compositions directed at specific needs. Also from an economical point of view, and from the point of view of minimising mistakes during processing, it is therefore advantageous to produce a single premix of components that can be used in the manufacture of several types of enteral clinical nutrition.
  • the module of components supports total methionine metabolism, it has universal benefit in many types of clinical nutrition.
  • the universal character of the food composition of the invention obviates the need to await the result of some types of clinical analyses of patients.
  • the module can be added in response to specific nutritional demands.
  • the compositions can be adapted for clinical nutrition, infant formulae, nutrition for persons at risk for specific diseases, enteral nutrition during pregnancy, and dietetic supplements.
  • the food compositions can be used for the treatment or prophylaxis of increased plasma level of homocysteine, cardiovascular diseases, imparted immune function, inflammatory diseases, autoimmune diseases such as arthritis, wound healing after surgery, decubitus, cancer, premature ageing, allergic conditions, neural disorders.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Seeds, Soups, And Other Foods (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)

Claims (12)

  1. Nahrungsmittelzusammensetzung, welche eine vollständige enterale Nahrung zur klinischen oder diätetischen Verwendung ist, enthaltend pro Tagesdosis:
    (a) einen Energiegehalt von 5.024 bis 10.467 kJ (1.200 bis 2.500 kcal), bereitgestellt durch Kohlenhydrate, Fette und eiweißhaltiges Material, wobei die Kohlenhydrate für mindestens 25% des Energiegehalts verantwortlich sind und das eiweißhaltige Material in einer Menge von mindestens 20 9 vorhanden ist, wobei mindestens 50% des eiweißhaltigen Materials als Proteine oder Peptide vorliegen, und
    (b) die folgenden Komponenten oder deren Emährungsäquivalente: 1,5 bis 7 g Methionin und Cystein zusammengenommen umfassend mindestens 0,5 g Cystein, 0.4 bis 8 mg Folsäure, 3,2 bis 20 mg Pyridoxal (Vitamin B6) und 24 bis 120 mg Zink.
  2. Nahrungsmittelzusammensetzung nach Anspruch 1, worin mindestens 30 Energie-% in der Form von Fetten sind und welche weiter mindestens 70 g eiweißhaltiges Material pro Tagesdosis, wobei mindestens 50% davon in der Form von Proteinen, wobei die Zusammensetzung optional in der Form von multiplen Dosiseinheiten ist.
  3. Nahrungsmittelzusammensetzung, welche eine enterale Nährungsergänzung zur klinischen oder diätetischen Verwendung ist, um sie zusätzlich zu einer nichtmedizinischen Nahrung zu verwenden, enthaltend pro Tagesdosis:
    (a) einen Energiegehalt von 1.675 bis zu weniger als 6.280 kJ (von 400 bis weniger als 1.500 kcal), bereitgestellt durch mindestens Kohlenhydrate und eiweißhaltiges Material, wobei lösliche verdauliche Kohlenhydrate in einer Menge von mindestens 100 g vorhanden sind und das eiweißhaltige Material in einer Menge von mindestens 20 g vorhanden ist, wobei mindestens 50% des eiweißhaltigen Materials als Proteine oder Peptide vorliegen, und
    (b) die folgenden Komponenten oder deren Ernährungsäquivalente: 0.6 bis 7 g Methionin und Cystein zusammengenommen, 0,4 bis 8 mg Folsäure, 3,2 bis 20 mg Pyridoxal (Vitamin 86), 24 bis 120 mg Zink und 0,3-6 g Betain.
  4. Nahrungsmittelzusammensetzung nach Anspruch 3, welche 1.675 bis 4.187 kJ (400 bis 1.000 kcal) pro Tagesdosis enthalt.
  5. Nahrungsmittelzusammensetzung nach einem der Ansprüche 1 bis 4, wobei mindestens eine der Komponenten in den folgenden Mengen pro Tagesdosis enthalten ist: Methionin und Cystein (1,6 bis 4 g), wobei Methionin mindestens die Hälfte dieser Menge ausmacht, Folsäure (0,6 bis 3 mg), Pyridoxal (4 bis 12 mg), Zink (30 bis 100 mg) und mindestens 3.350 kJ (800 kcal) in der Form von Kohlenhydraten.
  6. Nahrungsmittelzusammensetzung nach einem der Ansprüche 1 bis 5, welche weiter mindestens 0,8 g, vorzugsweise 1,6 bis 12 g Phospholipide pro Tagesdosis enthalt.
  7. Nahrungsmittelzusammensetzung nach einem der Ansprüche 1 bis 6, welche weiter mindestens eine der folgenden Komponenten oder deren Ernährungsäquivalente pro Tagesdosis umfasst:
    (a) Cyanocobalamin (Vitamin 812) (2 bis 20 µg, vorzugsweise 3,6 bis 10 µg), Magnesium (200 bis 700 mg, vorzugsweise 300 bis 500 mg) und Betain und/oder Cholin (0,3 bis 6, vorzugsweise 0,6 bis 3 g),
    (b) Kreatin (0,5 bis 40, vorzugsweise 2 bis 25 g), Carnitin (0,2 bis 4, vorzugsweise 0,4 bis 2 g), Taurin (15 bis 150, vorzugsweise 30 bis 80 mg) und Nukleotide (0,1 bis 4, vorzugsweise 0,4 bis 2 g),
    (c) Pyruvat (2 bis 20, vorzugsweise 4 bis 8 g), Riboflavin (Vitamin B2) (2 bis 10 mg, vorzugsweise 2,5 bis 6 mg), Niacin (25 bis 170 mg, vorzugsweise 35 bis 85 mg), Thiamin (2 bis 10 mg, vorzugsweise 3 bis 6 mg), D-Biotin (50 bis 500, vorzugsweise 100 bis 300 µg) und Thioctsäure (5 bis 200, vorzugsweise 10 bis 50 mg),
    (d) Mangan (9 bis 60 mg, vorzugsweise 10 bis 30 mg), Kupfer (3 bis 14 mg, vorzugsweise 4 bis 10 mg), Selen (80 bis 300 µg, vorzugsweise 100 bis 150 µg), Ascorbinsäure (Vitamin C) (100 bis 900 mg, vorzugsweise 150 bis 300 mg) und Tocopherol (Vitamin E) (15 bis 180 mg, vorzugsweise 20 bis 40 mg),
    (e) Serin (3 bis 12 g) und gegebenenfalls Arginin oder Omithin (2 bis 10 g), Glutamin (5 bis 30 g),
    wobei die Zusammensetzung weniger als 5,2 g Threonin pro 100 g eiweißhaltigem Material und vorzugsweise mindestens eine Komponente von jeder der Gruppen (a-e) enthält.
  8. Nahrungsmittelzusammensetzung nach einem der Anspruche 1 bis 7, welche 0,3 bis 6 g Betain pro Tagesdosis enthält.
  9. Nahrungsmittelzusammensetzung nach einem der Anspruche 1 bis 8, welche in einer flüssigen Form mit einer Energiedichte von mindestens 4,2 kJ bis zu 10,5 kJ/ml (1 bis 2,5 kcal/ml) vorliegt.
  10. Nahrungsmittelzusammensetzung nach einem der Anspruche 1 bis 8, welche in einer mit Wasser zu rekonstituierenden Pulverform vorliegt.
  11. Verfahren zur Herstellung einer Nahrungsmittelzusammensetzung nach einem der Ansprüche 1 bis 10, welche das Herstellen eines Vorgemisches von mindestens dem Methionin/Cystein, Folsäure, Pyridoxal und Zink, gegebenenfalls mit Kohlenhydrat als Träger, umfasst.
  12. Verwendung einer Zusammensetzung nach einem der Ansprüche 1 bis 10 zur Herstellung einer medizinischen Zusammensetzung für die Behandlung oder Prophylaxe von erhöhtem Plasmalevel von Homocystein, Herz-Kreislauferkrankungen, verschlechterter Immunfunktion, entzündlichen Erkrankungen, Autoimmunkrankheiten, Arthrose, Wundheilung nach Chirurgie, Decubitus, Krebs, vorzeitigem Altern, allergischen Bedingungen oder neuronalen Erkrankungen.
EP98935394A 1997-07-14 1998-07-14 Nahrungszusammensetzungen enthaltend methionin Revoked EP1001685B1 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP98935394A EP1001685B1 (de) 1997-07-14 1998-07-14 Nahrungszusammensetzungen enthaltend methionin
DK98935394T DK1001685T3 (da) 1997-07-14 1998-07-14 Næringsmiddelsammensætning indeholdende methionin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97202206A EP0891719A1 (de) 1997-07-14 1997-07-14 Narungszusammensetzungen mit Gehalt an Methionin
EP97202206 1997-07-14
EP98935394A EP1001685B1 (de) 1997-07-14 1998-07-14 Nahrungszusammensetzungen enthaltend methionin
PCT/NL1998/000408 WO1999003365A1 (en) 1997-07-14 1998-07-14 Nutritional composition containing methionine

Publications (2)

Publication Number Publication Date
EP1001685A1 EP1001685A1 (de) 2000-05-24
EP1001685B1 true EP1001685B1 (de) 2005-04-20

Family

ID=8228562

Family Applications (2)

Application Number Title Priority Date Filing Date
EP97202206A Withdrawn EP0891719A1 (de) 1997-07-14 1997-07-14 Narungszusammensetzungen mit Gehalt an Methionin
EP98935394A Revoked EP1001685B1 (de) 1997-07-14 1998-07-14 Nahrungszusammensetzungen enthaltend methionin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP97202206A Withdrawn EP0891719A1 (de) 1997-07-14 1997-07-14 Narungszusammensetzungen mit Gehalt an Methionin

Country Status (8)

Country Link
US (1) US6544547B2 (de)
EP (2) EP0891719A1 (de)
JP (1) JP2001510145A (de)
AT (1) ATE293367T1 (de)
AU (1) AU8465898A (de)
DE (1) DE69829853T2 (de)
DK (1) DK1001685T3 (de)
WO (1) WO1999003365A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004041270A1 (de) * 2004-08-26 2006-03-02 Merz Pharma Gmbh & Co. Kgaa Ein Kapillar- Wirksystem enthaltende Zusammensetzungen mit anwendungsbezogener Differenzierbarkeit und deren Verwendung
DE102005037298A1 (de) * 2005-08-08 2007-03-08 Christine Jaschek Verwendung von Kalium-, Magnesium-, Calcium- und Zink-Elektrolyten zur Behandlung des Elementemangel- und Austrocknungssyndroms Alzheimer und anderer Demenzen

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19817877C2 (de) * 1998-04-22 2002-06-13 Hans Guenter Berner Energy-Drink auf Fruchtsaftbasis
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
DK1100488T3 (da) * 1998-07-28 2003-08-11 Synthes Ag Anvendelse af creatinforbindelser til behandling af knogle- eller bruskceller og -væv
DE19856789A1 (de) 1998-12-09 2000-06-15 Nutricia Nv Thymuswachstumsstimulierende Säuglingsnahrung
DK0951842T3 (da) 1999-01-20 2003-01-06 Nutricia Nv Ernæringsprodukt til et spædbarn
EP1023843B1 (de) * 1999-01-29 2005-06-22 Sportmedizin Team Vertriebs GmbH Zusammensetzung zur Leistungsförderung bei sportlicher Tätigkeit, ihre Herstellung und Verwendung als diätetisches Lebensmittel
ES2250112T3 (es) 1999-03-08 2006-04-16 Medicure Inc. Analogos de piridoxal para el tratamiento de trastornos causados por carencia de vitamina b6.
FR2791571B1 (fr) * 1999-04-02 2002-10-04 Sod Conseils Rech Applic Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s)
WO2001000047A1 (en) * 1999-06-29 2001-01-04 The New Zealand Milk Institute Limited Prophylactic dietary supplement based on milk
US6489345B1 (en) 1999-07-13 2002-12-03 Medicure, Inc. Treatment of diabetes and related pathologies
IT1306173B1 (it) * 1999-07-23 2001-05-30 Sigma Tau Healthscience Spa Composizione per la prevenzione degli affaticamenti muscolari e permigliorare il rendimento energetico muscolare.
AU783855B2 (en) 1999-08-24 2005-12-15 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
US6479545B1 (en) * 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
WO2001056572A1 (en) * 2000-02-02 2001-08-09 Metagenics, Inc. Compositions and methods for promoting healthy joints
US8642581B1 (en) * 2000-02-11 2014-02-04 Brian D. Halevie-Goldman Compositions and methods for the production of S-adenosylmethionine within the body
US7442689B2 (en) 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
PT1268498E (pt) 2000-02-29 2005-07-29 Medicure Int Inc Fosfonatos cardioprotectores
CA2404329A1 (en) 2000-03-28 2001-10-04 Medicure International Inc. Treatment of cerebrovascular disease
CA2405377C (en) * 2000-04-18 2014-04-01 Societe Des Produits Nestle S.A. Nutritional modules
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US7208180B2 (en) 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
US6576634B1 (en) * 2000-07-07 2003-06-10 N.V. Nutricia Pharmaceutical or dietetic preparation for improvement of fertility and sperm quality
US6897228B2 (en) 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
WO2002004421A2 (en) 2000-07-07 2002-01-17 Medicure International Inc. Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
AU2000265516A1 (en) * 2000-08-11 2002-02-25 The Lawson Health Research Institute Compositions and methods for inhibiting islet dysfunction and autoimmune disorders
US6423349B1 (en) * 2000-08-24 2002-07-23 Baxter International, Inc. Therapeutic nutrient composition for pre and post elective surgery
US6579904B1 (en) 2000-09-22 2003-06-17 K.E.R. Associates, Inc. Process for making betaine transition metal complexes for use in animal feed supplements and compositions thereof
US7696219B2 (en) 2000-09-27 2010-04-13 Everett Laboratories, Inc. Method and composition for supplementation of nutritional deficiences in renal patients
US6995166B1 (en) * 2000-09-27 2006-02-07 Everett Laboratories, Inc. Method and composition for supplementation of nutritional deficiencies in renal patients
DE10057290B4 (de) * 2000-11-17 2004-01-08 Fresenius Kabi Deutschland Gmbh Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten
AU2002236527A1 (en) 2000-11-30 2002-06-11 The Health Research Institute Nutrient supplements and methods for treating autism and for preventing the onset of autism
US6716466B2 (en) * 2001-01-17 2004-04-06 Nestec S.A. Balanced food powder composition
US20020176881A1 (en) * 2001-01-26 2002-11-28 George Verlaan Rehydration composition
DE60212365T2 (de) 2001-04-25 2007-05-31 Cobalz Ltd., Chester Medizinische zusammensetzungen zur behandlung oder vorbeugung eines funktionellen vitamin b12 mangels
US6660293B2 (en) 2001-06-29 2003-12-09 Everett Laboratories, Inc. Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects
US7560123B2 (en) 2004-08-12 2009-07-14 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
GB2381451A (en) * 2001-11-01 2003-05-07 New Technology Res Ltd Pharmaco-dietary preparation having nutrition-supplementing and nutrition-enhancing effect
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
EP1327443A1 (de) * 2001-12-21 2003-07-16 Kyowa Hakko Kogyo Co., Ltd. Wirkstoffe zur Behandlung oder Prävention von Krankheiten, die durch eine reduzierte Expression des Klotho-Proteins verursacht wurden
WO2004000297A1 (en) * 2002-06-19 2003-12-31 N.V. Nutricia Nutritional or pharmaceutical compositions for increasing the creatine response of organisms
JP2005529980A (ja) * 2002-06-19 2005-10-06 ネムローゼ・フェンノートシャップ・ニュートリシア 代謝ストレスを受けている哺乳動物における異化を治療または予防し、同化を促進する方法及び組成物
US20040162292A1 (en) * 2002-12-03 2004-08-19 Evenstad Kenneth L. Multivitamin formulations for promoting healthy collagen, and methods of their use
JP2004203863A (ja) * 2002-12-09 2004-07-22 Taisho Pharmaceut Co Ltd 抗糖尿病用組成物
US8617617B2 (en) 2002-12-10 2013-12-31 Everett Laboratories, Inc. Methods and kits for co-administration of nutritional supplements
US6814983B2 (en) 2002-12-10 2004-11-09 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
EP1617734A1 (de) * 2003-04-17 2006-01-25 Boehringer Ingelheim International GmbH Multivitamin- und mineralstoffergänzung für schwangere
US20050013884A1 (en) * 2003-07-16 2005-01-20 Rennels M. Scott Compositions and methods for treating heart disease
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
DE10340845A1 (de) * 2003-09-04 2005-03-31 Flavin-Koenig, Dana F., Dr. Pharmazeutisches Kombinationspräparat, enthaltend Glycyrrhizinsäure, Zink und eine Verbindung, die eine Thiolgruppe oder eine zu dieser metabolisierbare Gruppe enthält
CN1889856B (zh) * 2003-10-16 2011-03-02 雀巢技术公司 对抗化疗法和放射疗法的副作用的营养组合物
US8377904B2 (en) 2004-02-09 2013-02-19 Hill's Pet Nutrition, Inc. Composition and method for use in cartilage affecting conditions
US20070043054A1 (en) * 2004-03-15 2007-02-22 Howard James R Enzyme cofactor combination for supplementing pyruvate dehydrogenase and alpha ketogluterate dehydrogenase complexes
US20050261367A1 (en) * 2004-03-29 2005-11-24 Howard Murad Methods for treating dermatological and other health-related conditions in a patient
US20070202153A1 (en) * 2004-04-09 2007-08-30 N.V. Nutricia Liquid Concentrated Formula
CA2570048A1 (en) * 2004-07-07 2006-01-12 Medicure International Inc. Combination therapies employing platelet aggregation drugs
US8101587B2 (en) 2004-08-12 2012-01-24 Everett Laboratories, Inc. Kits for nutrition supplementation
KR101217263B1 (ko) * 2004-08-27 2012-12-31 재단법인서울대학교산학협력재단 시스테인 또는 메타이오닌을 포함하는 갭 결합을 통한세포간 정보전달 억제 예방 및 치료용 조성물
WO2006050598A1 (en) 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
US7459468B2 (en) 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
US20060110501A1 (en) * 2004-11-22 2006-05-25 Axelrod Glen S Vaccinium injection molding
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
US8252742B2 (en) 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
CA2592844C (en) * 2004-12-30 2012-10-09 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
US9095164B2 (en) * 2005-02-09 2015-08-04 Kevin Meehan Animal feed composition for increased production of glutathione peroxidase and superoxide dismutase
US20080138483A1 (en) * 2005-02-09 2008-06-12 Kevin Meehan Animal feed composition for increased bioactivity and production of glutathione peroxidase and superoxide dismutase
CA2537452C (en) * 2005-03-09 2013-12-24 Abbott Laboratories Concentrated human milk fortifier liquid
CN101247833B (zh) * 2005-06-29 2013-02-13 希尔氏宠物营养品公司 预防和治疗炎性疾病的方法和组合物
BRPI0615396A2 (pt) * 2005-08-26 2011-05-17 Nestec Sa composição nutricional para a prevenção ou tratamento de má-nutrição em um paciente obeso, bem como uso de uma fonte de proteìna, vitamina a, vitamina c, vitamina e, zinco e selênio para sua preparação
WO2007059631A1 (en) * 2005-11-28 2007-05-31 Medicure International Inc. Selected dosage for the treatment of cardiovascular and related pathologies
US20090069638A1 (en) * 2005-12-02 2009-03-12 Howard Murad Diagnostic and Treatment Regimen for Achieving Body Water Homeostasis
ATE509624T1 (de) 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
AU2007233318B2 (en) * 2006-04-04 2011-06-02 Hill's Pet Nutrition, Inc. Compositions and methods for enhancing the antioxidant status of animals
US20070292535A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating arthritic and or osteoporitic conditions
US20070292529A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating osteoporotic conditions
MX2010000224A (es) 2007-06-26 2010-05-03 Nutricia Nv Mejoramiento de la memoria en individuos con mini-examen de estado mental de 24-26.
WO2009002145A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
WO2009002146A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
EP2214518A4 (de) * 2007-10-19 2011-06-29 Joel D Pardee Stoffwechselförderungstherapie
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
JPWO2009066562A1 (ja) * 2007-11-20 2011-04-07 明治乳業株式会社 赤血球系幹細胞の分化促進剤及び／又は増殖促進剤、並びに老人性貧血を防止又は治療するためのメチオニンの使用及びメチオニンを含む組成物
EP2222311B1 (de) 2007-12-20 2013-03-27 N.V. Nutricia Flüssiges nucleotide/nucleoside enthaltendes produkt
WO2010082390A1 (ja) * 2009-01-19 2010-07-22 ニュートリー株式会社 低濃度の栄養組成物
JP5682118B2 (ja) * 2009-02-17 2015-03-11 大正製薬株式会社 葉酸含有飲料
CA2778647A1 (en) 2009-11-25 2011-06-03 Nestec S.A. Nutritional compositions including a high protein component and exogenous nucleotides
WO2011100550A2 (en) 2010-02-12 2011-08-18 Alexander Vuckovic, M.D., Llc Compositions and methods for treating depression
FR2993780B1 (fr) * 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
IT1402330B1 (it) * 2010-09-03 2013-08-30 Poli Integratore alimentare
SG190087A1 (en) 2010-11-02 2013-06-28 Abbott Lab Stable concentrated liquid human milk fortifier
TWI561175B (en) * 2011-03-31 2016-12-11 Meiji Co Ltd Flowable nutrition composition containing l-arginine and method for producing the same
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
JP5997425B2 (ja) * 2011-08-18 2016-09-28 協和発酵バイオ株式会社 オルニチン含有組成物
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
JP2014159381A (ja) * 2013-02-19 2014-09-04 Kyowa Hakko Bio Co Ltd オルニチン含有体組成改善用組成物
GB2555024B (en) * 2015-06-08 2022-03-02 Halliburton Energy Services Inc Betaines for shale stabilization
WO2017059895A1 (en) 2015-10-07 2017-04-13 Parthenogen Sagl Dietary supplementation to achieve oxy-redox homeostasis and genomic stability
AU2017397463B2 (en) 2016-11-03 2022-01-06 HedoniaUSA, Inc. Compositions and methods for treating depression
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
EP3668499A1 (de) 2017-08-14 2020-06-24 Axcella Health Inc. Aminosäurezusammensetzungen zur behandlung von lebererkrankungen
WO2019246225A1 (en) 2018-06-20 2019-12-26 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
AU2019288371A1 (en) 2018-06-20 2020-12-03 Axcella Health Inc. Methods of manufacturing amino acid compositions
AU2020334128B2 (en) * 2019-08-21 2025-10-23 Brain Chemistry Labs Compositions comprising a metal and L-serine, and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4543262A (en) * 1983-03-30 1985-09-24 Nabisco Brands, Inc. Process for making a nutritional bar
US4871550A (en) * 1986-09-05 1989-10-03 Millman Phillip L Nutrient composition for athletes and method of making and using the same
US5132113A (en) * 1990-10-26 1992-07-21 Maurizio Luca Nutritional composition containing essential amino acids
US5215750A (en) * 1991-09-04 1993-06-01 Keane Ii Michael A L-glutamine and vitamin-containing compositions effective for inducing weight loss and for weight control
CA2078019C (en) * 1991-09-13 2002-08-27 Siegbert Heinrich Bissbort Substance or composition and uses thereof
US5480865A (en) * 1994-02-25 1996-01-02 Parkinson's Charitable Trust Nutritional composition
GB9416921D0 (en) * 1994-08-22 1994-10-12 Conway Gitta C A nutritional preparation
US5817329A (en) * 1997-02-28 1998-10-06 Gardiner; Paul T. Nutritional supplement for increased muscle size and strength for body builders

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004041270A1 (de) * 2004-08-26 2006-03-02 Merz Pharma Gmbh & Co. Kgaa Ein Kapillar- Wirksystem enthaltende Zusammensetzungen mit anwendungsbezogener Differenzierbarkeit und deren Verwendung
WO2006021278A1 (de) 2004-08-26 2006-03-02 Merz Pharma Gmbh & Co. Kgaa Ein kapillar- wirksystem enthaltende zusammensetzungen mit anwendungsbezogener differenzierbarkeit und deren verwendung
EP2269649A2 (de) 2004-08-26 2011-01-05 Merz Pharma GmbH & Co. KGaA Ein Kapillar-Wirksystem enthaltende Zusammensetzungen mit anwendungsbezogener Differenzierbarkeit und deren Verwendung
DE102005037298A1 (de) * 2005-08-08 2007-03-08 Christine Jaschek Verwendung von Kalium-, Magnesium-, Calcium- und Zink-Elektrolyten zur Behandlung des Elementemangel- und Austrocknungssyndroms Alzheimer und anderer Demenzen

Also Published As

Publication number Publication date
US20020142025A1 (en) 2002-10-03
ATE293367T1 (de) 2005-05-15
DE69829853D1 (de) 2005-05-25
AU8465898A (en) 1999-02-10
DE69829853T2 (de) 2006-03-02
EP1001685A1 (de) 2000-05-24
HK1028324A1 (en) 2001-02-16
US6544547B2 (en) 2003-04-08
DK1001685T3 (da) 2005-08-08
EP0891719A1 (de) 1999-01-20
JP2001510145A (ja) 2001-07-31
WO1999003365A1 (en) 1999-01-28

Similar Documents

Publication Publication Date Title
EP1001685B1 (de) Nahrungszusammensetzungen enthaltend methionin
US8450347B2 (en) Composition for relieving discomfort
EP0961552B1 (de) Zusatznahrung für kindpatienten
ES2263602T3 (es) Composicion que comprende aminoacidos libres.
CA2094540C (en) Orally-ingestible nutrition compositions having improved palatability
US3697287A (en) Amino acid food composition
US20020183263A1 (en) Nutritional preparation comprising ribose and medical use thereof
JPH07149664A (ja) 栄養補給剤
US20140037798A1 (en) Liquid nutritional products comprising metal amino acid chelates
NZ506272A (en) Calorically dense nutritional composition
MXPA06001706A (es) Jarabe multivitaminico para ninos o adultos jovenes.
KR101026331B1 (ko) 모유 보충물
HK1028324B (en) Nutritional compositions containing methionine
RU2018118799A (ru) Питательный продукт для снижения уровней фенилаланина у больных фку
HK1025017B (en) Nutritional support of paediatric patients

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000107

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK FI FR GB LI NL SE

17Q First examination report despatched

Effective date: 20031027

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: NUTRITIONAL COMPOSITIONS CONTAINING METHIONINE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HAGEMAN, ROBERT, JOHAN, JOSEPH

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK FI FR GB LI NL SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69829853

Country of ref document: DE

Date of ref document: 20050525

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1028324

Country of ref document: HK

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: FRESENIUS KABI DEUTSCHLAND GMBH

Effective date: 20060116

ET Fr: translation filed
NLR1 Nl: opposition has been filed with the epo

Opponent name: FRESENIUS KABI DEUTSCHLAND GMBH

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: N.V. NUTRICIA

Free format text: N.V. NUTRICIA#POSTBUS 1#2700 MA ZOETERMEER (NL) -TRANSFER TO- N.V. NUTRICIA#POSTBUS 1#2700 MA ZOETERMEER (NL)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20090722

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20090722

Year of fee payment: 12

Ref country code: GB

Payment date: 20090723

Year of fee payment: 12

Ref country code: FI

Payment date: 20090727

Year of fee payment: 12

Ref country code: DE

Payment date: 20090731

Year of fee payment: 12

Ref country code: CH

Payment date: 20090728

Year of fee payment: 12

Ref country code: AT

Payment date: 20090724

Year of fee payment: 12

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20090729

Year of fee payment: 12

RDAF Communication despatched that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSNREV1

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

27W Patent revoked

Effective date: 20091014

GBPR Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state

Effective date: 20091014

REG Reference to a national code

Ref country code: SE

Ref legal event code: ECNC

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF THE APPLICANT RENOUNCES

Effective date: 20050420

Ref country code: CH

Free format text: LAPSE BECAUSE OF THE APPLICANT RENOUNCES

Effective date: 20050420

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20100723

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20100722

Year of fee payment: 13